<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9023">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05706896</url>
  </required_header>
  <id_info>
    <org_study_id>4995</org_study_id>
    <nct_id>NCT05706896</nct_id>
  </id_info>
  <brief_title>Atrophic Age-related Macular Degeneration (AMD) Treated With Intravitreal Injections of Umbilical Cord Blood Platelet-rich Plasma (CB-PRP): a Pilot Study</brief_title>
  <acronym>CORD-IV</acronym>
  <official_title>Atrophic Age-related Macular Degeneration (AMD) Treated With Intravitreal Injections of Umbilical Cord Blood Platelet-rich Plasma (CB-PRP): a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study will be to evaluate the efficacy of intravitreal injections of&#xD;
      Umbilical Cord Blood Platelet-rich Plasma (CB-PRP) in order to reduce or stabilize the&#xD;
      atrophic progression in dry Age-related Macular Degeneration (AMD)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2022</start_date>
  <completion_date type="Anticipated">June 10, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 9, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomization will take place by eye, each patient will have one eye treated and the contralateral subjected to sham. The treated eye will receive CB-PRP injections modulated differently over time in each of the sub-studies, i.e. monthly, bimonthly or quarterly, while the contralateral eye will receive a SHAM injection.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Autofluorescence atrophy area changes in treated eyes compared with sham group</measure>
    <time_frame>1 year</time_frame>
    <description>Stabilization of enlargement of hypoautofluorescent area (atrophy) or at most a maximum increase of no more than 20% compared with baseline in treated subjects compared with placebo group from baseline until follow-ups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Autofluorescence atrophy area changes in treated eyes compared with sham group (1)</measure>
    <time_frame>1 year</time_frame>
    <description>Stabilization of the enlargement of the hyperfluorescent area (atrophy enhancement) or at most a maximum increase of not more than 20% from the baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ETDRS visual acuity</measure>
    <time_frame>1 year</time_frame>
    <description>Increase of at least two lines from baseline measurement and/or to the contralateral untreated eye at 3 and 6, 12, months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean increase in ONL thickness and retinal volumetrics</measure>
    <time_frame>1 year</time_frame>
    <description>Mean increase, measured by high-resolution quantitative OCT, of at least 20% from baseline at 3 and 6, 12, months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean increase in retinal volumetrics</measure>
    <time_frame>1 year</time_frame>
    <description>Mean increase, measured by high-resolution quantitative OCT, of at least 20% from baseline at 3 and 6, 12, months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stabilization of the atrophy region of the EPR</measure>
    <time_frame>1 year</time_frame>
    <description>Stabilization in enface OCT with less than 20% increase from baseline, comparing it with the placebo group, at 3 and 6, 12, months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinography of the ocular fundus</measure>
    <time_frame>1 year</time_frame>
    <description>Change in ocular fundus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incomplete retinal pigment epithelial (RPE) and outer retinal atrophy (iRORA)</measure>
    <time_frame>1 year</time_frame>
    <description>Change during follow ups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outer retinal atrophy (iRORA)</measure>
    <time_frame>1 year</time_frame>
    <description>Change during follow ups</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluation of therapy safety</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluation of major ocular adverse events (bacterial or fungal septic endophthalmitis, retinal detachment, vitreous proliferative-fibrotic reaction with retinal traction, secondary glaucoma, phthisis bulbs, iris rubeosis), studied at slit-lamp evaluation in the anterior and posterior chambers.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Dry Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Monthly injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will recive 12 intravitreal injections in one eye and 12 sham injections in the other eye each month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bimonthly injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will receive 6 intravitreal injections in one eye and 6 sham injections in the other eye each two months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quarterly injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will receive 4 intravitreal injections in one eye and 4 sham injections in the other eye each three months</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intravitreal injection of CB-PRP</intervention_name>
    <description>The procedure consists in a trans-scleral puncture to access the vitreous cavity, with subsequent injection of CB-PRP</description>
    <arm_group_label>Bimonthly injection</arm_group_label>
    <arm_group_label>Monthly injection</arm_group_label>
    <arm_group_label>Quarterly injection</arm_group_label>
    <other_name>CB-PRP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥65 years&#xD;
&#xD;
          -  Bilateral dry-AMD&#xD;
&#xD;
          -  ETDRS-corrected visual acuity between (or equal to) 1/10 and 4/10&#xD;
&#xD;
          -  No concomitant ocular pathology (e.g., Glaucoma, amblyopia) or systemic pathology that&#xD;
             would result in a BIAS for primary goal assessment&#xD;
&#xD;
          -  Signature of informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 65 years&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Previous inflammatory/infectious events involving the eyes&#xD;
&#xD;
          -  Eye trauma, diabetes, or disease potentially damaging to the visual system, even in&#xD;
             the absence of impairment at the time of intake&#xD;
&#xD;
          -  Previous intravitreal treatments.&#xD;
&#xD;
          -  Refusal to sign informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Cristina Savastano</last_name>
      <phone>+39 3384443002</phone>
      <email>mariacristina.savastano@unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Maria Cristina Savastano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2022</verification_date>
  <study_first_submitted>January 9, 2023</study_first_submitted>
  <study_first_submitted_qc>January 23, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2023</study_first_posted>
  <last_update_submitted>January 23, 2023</last_update_submitted>
  <last_update_submitted_qc>January 23, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

